Order Article Reprints

Akbar SMF, Al Mahtab M, Aguilar JC, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial. Pathogens. 2021; 10(11):1440. https://doi.org/10.3390/pathogens10111440

Akbar, Sheikh Mohammad Fazle, Mamun Al Mahtab, Julio Cesar Aguilar, Osamu Yoshida, Eduardo Penton, Guillen Nieto Gerardo, and Yoichi Hiasa. 2021. "Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial" Pathogens 10, no. 11: 1440. https://doi.org/10.3390/pathogens10111440

Akbar, S. M. F., Al Mahtab, M., Aguilar, J. C., Yoshida, O., Penton, E., Gerardo, G. N., & Hiasa, Y. (2021). Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial. Pathogens, 10(11), 1440. https://doi.org/10.3390/pathogens10111440